Future research on different PSMA tracers should include prospective studies to validate these findings, as well as studies directly comparing the diagnostic accuracy of these tracers in detecting prostate cancer lesions, particularly in cases of biochemical recurrence or small-volume metastatic disease. This evidence concerns the gene FOLH1 and Familial prostate cancer.